文献速递慢性肾脏病血液净化与透析

恩格列净对2型糖尿病患者肾功能下降的影响:EMPA-REG OUTCOME试验的斜率分析

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
PubMed 文献 · J Am Soc Nephrol · 2018-10-12

该研究基于EMPA-REG OUTCOME试验中7020例2型糖尿病合并心血管疾病患者,采用随机截距/随机斜率模型分析eGFR斜率。结果显示恩格列净在治疗初期使eGFR斜率下降,但长期维持期斜率优于安慰剂,停药后eGFR回升,提示其血流动力学效应对长期肾功能有保护作用。

要点

  • 恩格列净治疗初期eGFR斜率下降,但长期维持期eGFR年下降幅度显著小于安慰剂。
  • 停药后仅恩格列净组eGFR斜率回升并向基线恢复,支持血流动力学机制。
  • 在高CKD风险亚组中结果一致,提示恩格列净的肾脏保护作用具有普遍性。

核心结论

  • 恩格列净通过血流动力学效应降低肾小球内压力,可能有助于长期保持肾功能。

研究设计与样本

  • EMPA-REG OUTCOME试验的事后斜率分析,纳入7020例2型糖尿病合并心血管疾病患者,随机1:1:1接受恩格列净10mg/d、25mg/d或安慰剂。
  • 采用随机截距/随机系数模型计算预设研究阶段的eGFR斜率:治疗起始期(基线至第4周)、慢性维持期(第4周至治疗末次值)、治疗后(治疗末次值至随访)。

主要发现

  • 治疗起始期,恩格列净组调整后平均eGFR斜率(每周变化,ml/min per 1.73 m2)为-0.77(95%CI -0.83至-0.71),安慰剂组为0.01(95%CI -0.08至0.10),P<0.001。
  • 慢性维持期,恩格列净组年eGFR斜率(ml/min per 1.73 m2 per year)为0.23(95%CI 0.05至0.40),安慰剂组为-1.46(95%CI -1.74至-1.17),P<0.001。
  • 停药后,恩格列净组调整后平均eGFR斜率(每周变化,ml/min per 1.73 m2)为0.56(95%CI 0.49至0.62),安慰剂组为-0.02(95%CI -0.12至0.08),P<0.001;仅恩格列净组eGFR向基线水平回升。
  • 在高CKD风险亚组中,结果保持一致。

临床怎么用

  • 恩格列净治疗初期eGFR下降属预期血流动力学效应,不应因此停药。
  • 长期使用恩格列净可减缓eGFR年下降速度,对2型糖尿病合并心血管疾病患者具有肾脏保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. METHODS: Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up). RESULTS: Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m2) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; P<0.001). However, annual mean slope (ml/min per 1.73 m2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: -1.46; 95% confidence interval, -1.74 to -1.17; P<0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo -0.02; 95% confidence interval, -0.12 to 0.08; P<0.001). Results were consistent across patient subgroups at higher CKD risk. CONCLUSIONS: The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol. 2018. PMID: 30314978. doi:10.1681/ASN.2018010103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。